Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Massachusetts for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Massachusetts only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Massachusetts (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

David Reed (NPI 1932330990)

Field	Value
Entity Type	Individual
Organization	David Reed
Address	146 Industrial Park Rd
City	Plymouth
State	MA
ZIP	02360
Taxonomy	Retina Specialist (Ophthalmology) Physician
NPI Enumerated	August 6, 2009

Payer Source	Total Paid
Medicare	$7.7M
Medicaid	$0

Key Findings

Practice profile: DAVID REED is a retina-focused ophthalmology physician with a billing mix dominated by intravitreal drug administration and retina diagnostics; the top Medicare services are J0178 (aflibercept injections, 7.4K claims, $5.1M revenue), J2777 (faricimab, 34.3K claims, $995.5K revenue), and 67028 (isolated intravitreal injection procedure, 5K claims, $487.5K revenue). The presence of high-volume injection codes alongside high volumes of retinal imaging and follow-up visits suggests an in-office, procedure-centric retina practice model.

Revenue concentration: top 3 Medicare codes by revenue account for 85.5% of this provider's total Medicare revenue, with J0178 alone representing 66.3% of Medicare dollars. This level of concentration indicates heavy dependence on anti-VEGF therapy (primarily aflibercept) as the principal revenue driver for the practice.

Payer mix: Total Medicare revenue: $7.7M versus Total Medicaid revenue: none (no Medicaid billing on file), so the provider is effectively single-payer with Medicare as the dominant — and sole reported — public payer. Analysts should treat market exposure and revenue projections for this NPI as fully Medicare-driven given the absence of Medicaid activity.

Competitive standing on injections: the provider is an extreme national outlier on key injection metrics — J0178 ranks #5 of 3204 providers nationally (100th percentile; extreme outlier) and 67028 ranks #8 of 4255 providers nationally (100th percentile; extreme outlier). Those ranks indicate a national-scale injection volume that substantially exceeds typical peers and positions this clinician as a major high-volume injector for aflibercept and related intravitreal procedures.

Variation across agents: although J2777 (faricimab) contributes $995.5K (12.9% of Medicare revenue) and shows high absolute claims (34.3K), it ranks #234 of 2039 (89th percentile; typical, unremarkable volume), indicating that usage of newer agents is substantial but not as extreme relative to national peers as aflibercept. The practice also bills J9035 (bevacizumab, 1.6K claims, $85.3K revenue; 98th percentile; notably above typical), and Q5124 (biosimilar ranibizumab, 1.1K claims, $172.4K revenue) which together show diversification across anti-VEGF products.

Integrated diagnostic and follow-up services: high volumes of retinal diagnostics and E/M visits support the procedural activity — 92134 has 7.8K claims and $241.7K revenue and ranks #4 of 26868 nationally (100th percentile; extreme outlier), while 92014 has 3.4K claims and $306.5K revenue and ranks #36 of 35415 nationally (100th percentile; extreme outlier). This pattern is consistent with an in-office workflow that combines frequent injections with same-site imaging and established-patient follow-ups.

Operational longevity and scale: NPI enumerated (registered) 2009-08-06 (~17 years ago) with lifetime Medicare revenue of $7.7M, indicating a well-established practice sustaining large procedural volumes over time. The combination of long tenure and outsized national ranks for multiple retina procedures suggests durable capacity and a stable referral/volume base.

Risk and strategic implications: the practice’s heavy reliance on a small set of high-revenue CPT/HCPCS codes (top 3 = 85.5% of Medicare revenue) concentrates financial risk in anti-VEGF treatment patterns and reimbursement for intravitreal injections. Payer negotiations, formulary or coverage changes for these agents, or shifts in treatment protocols would disproportionately affect this provider’s revenue given the near-absence of Medicaid revenue and the Medicare-centric revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

20 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J0178	Injection, aflibercept, 1 mg	7,410	$690	$5.1M
J2777	Injection, faricimab‑svoa, 0.1 mg	34,330	$30	$995.5K
67028	The provider injects a medication into the vitreous chamber of the eye as an isolated procedure or a separate procedure unrelated to any other procedure being performed on the eye.	4,970	$100	$487.5K
92014	An ophthalmologist sees an established patient for a comprehensive level eye examination. Generally, a patient is considered to be "established" if the same physician, or any physician in the group…	3,370	$90	$306.5K
92134	The provider performs computerized diagnostic imaging of the retina in the posterior segment (back part) of the eye, interprets the data, and provides a report. The service may be on one or both eyes.	7,800	$30	$241.7K
Q5124	Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg	1,110	$160	$172.4K
J2778	Injection, ranibizumab, 0.1 mg	550	$180	$99.9K
J9035	Injection, bevacizumab, 10 mg	1,550	$60	$85.3K
J7312	Injection, dexamethasone, intravitreal implant, 0.1 mg	310	$160	$48.7K
J3490	Unclassified drugs	20	$1,750	$36.7K

Showing 1–10 of 20

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 20 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Massachusetts Distribution

David Reed — 9 of 20 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Massachusetts

Full comparison — all codes billed, vs. state median

20 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J0178	2	90	790	$690	$826.5K
J2777	1	50	7,080	$30	$343.1K
J2778	16	30	560	$180	$200.7K
Q5124	4	10	800	$160	$186K
67028	2	120	570	$100	$80.7K
J3490	19	20	60	$380	$49.5K
J7312	1	10	220	$160	$35.7K
92014	2	1,070	160	$90	$30.1K
67042	3	30	20	$1,170	$25.7K
J9035	3	80	250	$50	$19.7K

Showing 1–10 of 20

Related Providers

Other providers that share a Tax Identification Number (TIN) with David Reed, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
The General Hospital Corporation	MA	General Acute Care Hospital	$0	$438M
Community Physicians Of Indiana Inc	IN	Family Medicine Physician	$0	$185M
Massachusetts General Physicians Organization Inc	MA	Dermatology Physician	$0	$60.2M
Boston Emergency Physician Foundation, Inc.	MA	Emergency Medicine Physician	$0	$24.3M
Colorado Permanente Medical Group, P.C.	CO	Internal Medicine Physician	$0	$23.2M
Alok Bansal	CA	Ophthalmology Physician	$3M	$4.7M
Torsten Wiegand	MA	Retina Specialist (Ophthalmology) Physician	$7.6M	$0
Omesh Gupta	PA	Ophthalmology Physician	$7.1M	$80
Mitchell Fineman	PA	Ophthalmology Physician	$7M	$0
Richard Kaiser	PA	Ophthalmology Physician	$6.6M	$0

Nearby Providers

Other providers in the same ZIP code as David Reed, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Commonwealth Of Massachusetts	MA	Case Management Agency	$0	$316.5M
Centrus Premier Home Care Inc	MA	Home Health Agency	$0	$201.1M
Pediatric Services Of America, LLC	MA	Home Health Agency	$0	$21.9M
The Arc Of Greater Plymouth	MA	Foster Care Agency	$0	$12M
Beth Israel Deaconess Hospital Plymouth, Inc.	MA	Community Based Hospice Care Agency	$0	$11.5M
Harbor Health Services, Inc.	MA	Community Health Clinic/Center	$0	$7.7M
Habilitation Assistance Corporation	MA	Developmentally Disabled Services Day Training Agency	$0	$7.6M
Commonwealth Of Massachusetts-dmh	MA	Case Management Agency	$0	$6.6M
Plymouth Laser Center, P.C.	MA	Ambulatory Surgical Clinic/Center	$2.2M	$157.2K
Bernard Durante	MA	Otolaryngic Allergy Physician	$1.1M	$185.3K

David Reed — Billing Profile & Reimbursement Data

Sign up for David Reed — Billing Profile & Reimbursement Data policy alerts

David Reed — Billing Profile & Reimbursement Data

Sign up for David Reed — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References